Navigation Links
Forever young: Differentiation blocked in tumor stem cells
Date:1/7/2008

A new comparison of normal stem cells and cancer stem cells reveals that the cancer stem cells are abnormally trapped at an early stage of development. The research, published by Cell Press in the January issue of Cancer Cell, significantly advances the understanding of glioma pathophysiology and provides new directions for design of therapeutic strategies that are targeted to specific types of tumors.

Tumor-initiating cells with stem like properties (TICs) are thought to be a small population of tumor cells that have many characteristics in common with normal stem cells (NSCs) in that they are self-replicating and capable of giving rise to populations of differentiated cells. Previous research has demonstrated that TICs are present in different types of brain tumors, including glioblastomas. Although the TICs share many properties with NSCs, they are known to possess genetic aberrations that support a tumorigenic phenotype.

Thus far, there have been few, if any, reports demonstrating exactly where along the developmental pathway of tissue-specific stem cell maturation and differentiation tumor stem cells arise, and which, if any, of the intrinsic stem cell signaling pathways are perturbed in tumor stem cells remains largely unknown, explains Dr. Howard A. Fine from the National Cancer Institute in Bethesda, Maryland. To better understand the development and differentiation pathways that play a significant role in cancer stem cells, Dr. Fine and colleagues isolated TICs from primary human glioblastomas and compared them to human and mouse NSCs at various developmental stages.

The researchers found that the TICs isolated from an adult patient are more similar to early embryonic stem cells than to later embryonic or adult-derived stem cells. Specifically, the TICs appear to be stuck at this early developmental stage, at least in part, due to epigenetic repression of bone morphogenic protein receptor 1B (BMPR1B) expression mediated through a polycomb repressive complex. BMPs are known to mediate proliferation, differentiation and apoptosis in NSCs, depending on the stage of cell development and the local environment. Importantly, forced expression of the silenced BMPR1B restored normal differentiation capacity to the isolated TICs, halting further cell division and inducing terminal differentiation.

Our research provides an example of a temporally deregulated and aberrantly fixed normal stem cell developmental block to differentiation contributing to the pathogenesis of a human tumor. Not only will such insights pave the way for a more thorough understanding of tumor stem cell biology, but they also identify BMPR1B as a promising molecular target and open the potential for targeted therapeutic approaches for agents that can induce terminal differentiation of tumor stem cells, offers Dr. Fine.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure
2. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
5. Study details regulation of vital tumor suppressor gene p53
6. Human C-reactive protein regulates myeloma tumor cell growth and survival
7. Customized virus kills brain tumor stem cells that drive lethal cancer
8. Study suggests brain tumors need treatment with multiple targeted drugs
9. Bright tumors, dim prospects
10. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
11. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise level ... as Vice President of Sales. Cifolelli’s primary responsibilities include management of the ... rapidly expanding field of organizational social engineering. , “We are delighted to ...
(Date:5/24/2016)... Orion, Clarkston Michigan (PRWEB) , ... May 24, ... ... new Certified Nurse Midwife, Roberta Jordan. , Roberta Jordan is a Certified ... degree from Grand Valley State University and then went on to complete her ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... advisory organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... consultative approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. ...
(Date:5/24/2016)... ... 2016 , ... Local engineering firm, Timmons Group, announced the ... in Woodbridge, VA. The project includes a brand new operating room addition ... new 2 story building houses the Central Sterile department, Sterile prep area and ...
(Date:5/24/2016)... ... ... Mental health watchdog Citizens Commission on Human Rights (CCHR) of Georgia, ... Szasz, is continuing its protest against the use of electroshock (ECT) on children with ... opening of the exhibit follows CCHR’s recent protest at the annual convention of the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology: